Mohammad S Siddiqui1, Raj Vuppalanchi1, Mark L Van Natta2, Erin Hallinan2, Kris V Kowdley3, Manal Abdelmalek4, Brent A Neuschwander-Tetri5, Rohit Loomba6, Srinivasan Dasarathy7, Danielle Brandman8, Edward Doo9, James A Tonascia2, David E Kleiner10, Naga Chalasani11, Arun J Sanyal1. 1. Division of Gastroenterology & Hepatology, Virginia Commonwealth University, Richmond, Virginia. 2. Department of Epidemiology, The Johns Hopkins University School of Public Health, Baltimore, Maryland. 3. Division of Gastroenterology & Hepatology, Swedish Medical Center, Seattle, Washington. 4. Division of Gastroenterology & Hepatology, Duke University, Durham, North Carolina. 5. Division of Gastroenterology & Hepatology, Saint Louis University, St Louis, Missouri. 6. Division of Gastroenterology & Hepatology, University of California San Diego, San Diego, California. 7. Division of Gastroenterology & Hepatology, Cleveland Clinic Foundation, Cleveland, Ohio. 8. Division of Gastroenterology & Hepatology, University of California at San Francisco, San Francisco, California. 9. Liver Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. 10. National Cancer Institute, Bethesda, Maryland. 11. Division of Gastroenterology & Hepatology, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address: nchalasa@iu.edu.
Abstract
BACKGROUND & AIMS: Vibration-controlled transient elastography (VCTE), which measures liver stiffness, has become an important tool for evaluating patients with nonalcoholic fatty liver disease (NAFLD). We aimed to determine the diagnostic accuracy of VCTE in detection of NAFLD in a multicenter cohort of patients. METHODS: We performed a prospective study of 393 adults with NAFLD who underwent VCTE within 1 year of liver histology analysis (median time, 49 d; interquartile range, 25-78 d), from July 1, 2014, through July 31, 2017. Liver stiffness measurement (LSM) cut-off values for pairwise fibrosis stage and controlled attenuation parameter cut-off values for pairwise steatosis grade were determined using cross-validated area under the receiver operating characteristics curve (AUROC) analyses. Diagnostic statistics were computed at a sensitivity fixed at 90% and a specificity fixed at 90%. RESULTS: LSM identified patients with advanced fibrosis with an AUROC of 0.83 (95% CI, 0.79- 0.87) and patients with cirrhosis with an AUROC of 0.93 (95% CI, 0.90-0.97). At a fixed sensitivity, a cut-off LSM of 6.5 kPa excluded advanced fibrosis with a negative predictive value of 0.91, and a cut-off LSM of 12.1 kPa excluded cirrhosis with a negative predictive value of 0.99. At a fixed specificity, LSM identified patients with advanced fibrosis with a positive predictive value of 0.71 and patients with cirrhosis with a positive predictive value of 0.41. Controlled attenuation parameter analysis detected steatosis with an AUROC of 0.76 (95% CI, 0.64-0.87). In contrast, the VCTE was less accurate in distinguishing lower fibrosis stages, higher steatosis grades, or the presence of NASH. CONCLUSIONS: In a prospective study of adults with NAFLD, we found VCTE to accurately distinguish advanced vs earlier stages of fibrosis, using liver histology as the reference standard.
BACKGROUND & AIMS: Vibration-controlled transient elastography (VCTE), which measures liver stiffness, has become an important tool for evaluating patients with nonalcoholic fatty liver disease (NAFLD). We aimed to determine the diagnostic accuracy of VCTE in detection of NAFLD in a multicenter cohort of patients. METHODS: We performed a prospective study of 393 adults with NAFLD who underwent VCTE within 1 year of liver histology analysis (median time, 49 d; interquartile range, 25-78 d), from July 1, 2014, through July 31, 2017. Liver stiffness measurement (LSM) cut-off values for pairwise fibrosis stage and controlled attenuation parameter cut-off values for pairwise steatosis grade were determined using cross-validated area under the receiver operating characteristics curve (AUROC) analyses. Diagnostic statistics were computed at a sensitivity fixed at 90% and a specificity fixed at 90%. RESULTS: LSM identified patients with advanced fibrosis with an AUROC of 0.83 (95% CI, 0.79- 0.87) and patients with cirrhosis with an AUROC of 0.93 (95% CI, 0.90-0.97). At a fixed sensitivity, a cut-off LSM of 6.5 kPa excluded advanced fibrosis with a negative predictive value of 0.91, and a cut-off LSM of 12.1 kPa excluded cirrhosis with a negative predictive value of 0.99. At a fixed specificity, LSM identified patients with advanced fibrosis with a positive predictive value of 0.71 and patients with cirrhosis with a positive predictive value of 0.41. Controlled attenuation parameter analysis detected steatosis with an AUROC of 0.76 (95% CI, 0.64-0.87). In contrast, the VCTE was less accurate in distinguishing lower fibrosis stages, higher steatosis grades, or the presence of NASH. CONCLUSIONS: In a prospective study of adults with NAFLD, we found VCTE to accurately distinguish advanced vs earlier stages of fibrosis, using liver histology as the reference standard.
Authors: Don C Rockey; Stephen H Caldwell; Zachary D Goodman; Rendon C Nelson; Alastair D Smith Journal: Hepatology Date: 2009-03 Impact factor: 17.425
Authors: Sun Gyo Lim; Sung Won Cho; Yoon Chul Lee; Su Jin Jeon; Myoung Hee Lee; Young Ju Cho; Soon Sun Kim; Young Bae Kim; Jae Yeon Seok; Jae Youn Cheong; Jin Hong Kim Journal: Hepatogastroenterology Date: 2011 Mar-Apr
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Charlie C Park; Phirum Nguyen; Carolyn Hernandez; Ricki Bettencourt; Kimberly Ramirez; Lynda Fortney; Jonathan Hooker; Ethan Sy; Michael T Savides; Mosab H Alquiraish; Mark A Valasek; Emily Rizo; Lisa Richards; David Brenner; Claude B Sirlin; Rohit Loomba Journal: Gastroenterology Date: 2016-10-27 Impact factor: 22.682
Authors: Stephen H Caldwell; Vanessa D Lee; David E Kleiner; Abdullah M S Al-Osaimi; Curtis K Argo; Patrick G Northup; Carl L Berg Journal: Ann Hepatol Date: 2009 Oct-Dec Impact factor: 2.400
Authors: Samer Gawrieh; Laura A Wilson; Oscar W Cummings; Jeanne M Clark; Rohit Loomba; Bilal Hameed; Manal F Abdelmalek; Srinivasan Dasarathy; Brent A Neuschwander-Tetri; Kris Kowdley; David Kleiner; Edward Doo; James Tonascia; Arun Sanyal; Naga Chalasani Journal: Am J Gastroenterol Date: 2019-10 Impact factor: 10.864
Authors: Katharina Staufer; Emina Halilbasic; Walter Spindelboeck; Magdalena Eilenberg; Gerhard Prager; Vanessa Stadlbauer; Andreas Posch; Petra Munda; Rodrig Marculescu; Barbara Obermayer-Pietsch; Judith Stift; Carolin Lackner; Michael Trauner; Rudolf E Stauber Journal: United European Gastroenterol J Date: 2019-07-12 Impact factor: 4.623
Authors: Naga Chalasani; Shusuke Toden; John J Sninsky; Richard P Rava; Jerome V Braun; Samer Gawrieh; Jiali Zhuang; Michael Nerenberg; Stephen R Quake; Tara Maddala Journal: Am J Physiol Gastrointest Liver Physiol Date: 2021-01-27 Impact factor: 4.052